The death ligand TRAIL has been suggested as a suitable biological agent for the selective induction of cell death in cancer cells. Moreover, TRAIL synergizes with DNAdamaging therapies such as chemotherapeutic drugs or ionizing irradiation (IR). Here, we show that synergy of TRAIL and IR, that is, crosssensitization between TRAIL and IR for induction of apoptosis, entirely depends on Bax proficiency in human DU145 and HCT116 carcinoma cells. DU145 prostate carcinoma cells that have lost Bax protein expression due to mutation fail to activate caspase-3 and -9 when exposed to TRAIL and IR. In contrast, TRAIL sensitized for IR-induced apoptosis and vice versa upon reconstitution of Bax expression. Notably, both DU145 and HCT116 still express significant levels of the multidomain proapoptotic Bcl-2 homolog Bak. This indicates that Bak is not sufficient to mediate crosssensitization and synergism between IR and TRAIL. These data clearly establish distinct roles for Bax and Bak in linking the TRAIL death receptor pathway to the mitochondrial apoptosis signaling cascade upon DNA damage by IR.
Introduction
Abrogation of tumor cell proliferation and complete elimination of tumor cells through activation of cell death programs is the ultimate goal in cancer therapy. Inactivation of key cellular signaling modules mediating these therapeutic effects is, however, a frequent event in malignant tumors. While disruption of cell cycle checkpoint control results in unrestricted proliferation of cancer cells, loss of apoptosis programs is one of the key reasons for development of resistance to ionizing irradiation (IR) and chemotherapy. Therefore, cancer therapy exerts a significant selection pressure for tumor cell subclones that display inactivation of key cell death regulators. Such deregulation of cell death signaling may occur at any step of the signaling cascade and frequently affects upstream regulators such as p53, components of the mitochondrial death machinery or downstream effectors such as caspases (Friedrich et al., 2001; Bosanquet et al., 2002; Sturm et al., 2002; Gillissen et al., 2003) .
In contrast to the mitochondrial pathway, disruption of the death receptor-regulated apoptosis signaling is not a major mechanism in the development of acquired resistance to drug-or irradiation-induced apoptosis (Wesselborg et al., 1999; Engels et al., 2000; Newton and Strasser, 2000; Wieder et al., 2001) . Thus, the vast majority of human malignancies has retained the propensity to undergo apoptosis upon triggering either the CD95/Fas and/or the TRAIL receptors (Ashkenazi et al., 1999; Eberle et al., 2003) . In fact, a variety of recent reports impressively demonstrated that TRAIL (von Haefen et al., 2004) and other death ligands including CD95/Fas and TNFa (Schmelz et al., 2004) can be readily employed to sensitize tumor cells for drug-induced apoptosis (reviewed in Daniel et al., 2001) .
In contrast to death receptor-mediated cell death signaling, the mitochondrial pathway of apoptosis exerts a key role in drug-induced apoptosis (von Haefen et al., 2003) . Exposure to anticancer drugs induces the mitochondrial apoptosis pathway through a Bax and Bak-dependent mechanism that results in release of proapoptotic factors from the mitochondria . These include cytochrome c, and Smac, the second mitochondrial activator of apoptosis, and the apoptosis-inducing factor AIF (Martinou and Green, 2001; van Loo et al., 2002) . While AIF executes an apoptosis-like but caspase-independent mode of cell death, both cytochrome c and Smac initiate and amplify the caspase cascade and execution of apoptosis (Deng et al., 2002) . Cytochrome c, the CARD adapter protein APAF-1, and procaspase-9 associate in an ATP/dATP-dependent manner in the cytosol to form the apoptosome that mediates procaspase-9 activation (Martinou and Green, 2001 ). Active caspase-9 then mediates cleavage of the effector caspases-3, -6, and -7. Cytosolic Smac was demonstrated to alleviate IAPmediated repression of caspase activation and to facilitate activation of caspases-9 and -3 (Wu et al., 2000; Hasenja¨ger et al., 2004) .
Disruption of mitochondrial apoptosis signaling and concomitant development of resistance to anticancer therapy occurs, for example, as a consequence of overexpression of antiapoptotic members of the Bcl-2 family such as Bcl-2 or Bcl-x L , or through the loss of proapoptotic Bcl-2 homologs such as Bax or Bak (reviewed in Daniel et al., 2003) . In this vein, we previously demonstrated that loss of Bax is associated with a shorter overall survival of patients with gastrointestinal carcinomas (Sturm et al., 1999 Gu¨ner et al., 2002; Mrozek et al., 2002; Schelwies et al., 2002) . Similarly, loss of Bax was associated with resistance to anthracyclin inhibitors of topoisomerase II, DNA damage by alkylating agents, and spindle damage by vinca alkaloids in B cellular chronic lymphocytic leukemia or calicheamicin, the toxin compound of the immunotoxin gemtuzumab ozogamicin (Mylotarg) (Prokop et al., 2003) .
To functionally address these phenomena, we reexpressed Bax von Haefen et al., 2002) or overexpressed the Bax homolog Bak or the BH3-only protein Nbk to revert acquired resistance to drug-induced apoptosis (Radetzki et al., 2002; Gillissen et al., 2003) . These studies delineated that loss of activators of the mitochondrial apoptosis signaling cascade is a key event in the development of resistance to anticancer therapy.
Interestingly, part of the signaling cascade of death receptor signaling is also utilized during drug-or irradiation-induced apoptosis. Both IR and a variety of anticancer drugs were shown to trigger death receptor-independent processing and activation of procaspase-8 that occurs through a caspase-3-dependent mechanism . Both caspase-8 and -3 are critically involved in a positive feedback amplification loop of cytochrome c release that initiates the caspase cascade and results in cleavage of the BH3-only protein Bid (Slee et al., 2000) . This feedback amplification is required for full release of cytochrome c and processing of caspase-9 and -3 activation and can be disrupted by overexpression of Bcl-2 (von Haefen et al., 2003) .
Given the frequent inactivation of the proapoptotic Bcl-2 homolog Bax in human malignancies, we aimed to investigate the impact of Bax loss on TRAIL sensitivity and sensitization for apoptosis induced by IR. Here, we show that TRAIL entirely depends on Bax to mediate induction of apoptosis. Likewise, the synergistic effect of TRAIL on IR-induced apoptosis fully depends on the presence of Bax, whereas Bak is clearly not sufficient to mediate the synergistic interaction between TRAIL and IR. This clearly supports recent findings on the distinct roles of proapoptotic multidomain Bcl-2 homologs and assigns distinct roles to Bax and Bak in cell death control upon IR.
Results

Role of Bax in apoptosis induced by TRAIL and irradiation
Anticancer drugs like nucleoside analogs (Klo¨pfer et al., 2004) , anthracyclines , or taxanes (von Haefen et al., 2003) trigger apoptotic cell death through the death receptor-independent induction of the mitochondrial apoptosis pathway. This occurs through a Bcl-2-dependent sensitive signaling event that involves multidomain proapoptotic Bcl-2 homologs, that is, Bax and Bak. While some stimuli depend entirely on Bax , others like the antimetabolite 5-FU signal via both Bax and Bak (von Haefen et al., 2004) . Therefore, and in view of the frequent disruption of Bax in malignant tumors, we aimed to functionally dissect the role of Bax in apoptosis induced by IR and sensitization for IR-induced cell death by TRAIL. As experimental systems, we employed DU145 and HCT116 cells. DU145 is a prostate carcinoma cell line that carries both a loss-of-function p53 mutation and a monoallelic Bax frameshift mutation and a second silent Bax allele. Consequently, DU145 cells are completely void of Bax protein expression, whereas Bak can be readily detected Prokop et al., 2003; von Haefen et al., 2004) . In these cells, we reconstituted Bax protein expression by the use of a retroviral vector Bax-HyTK (von Haefen et al., 2003) . Re-expression of Bax fully restored sensitivity, that is, for ceramide-or epirubicin-induced apoptosis von Haefen et al., 2003) . In contrast, HCT116 colon carcinoma cells express wild-type p53 and Bax. There, the Bax gene was disrupted by targeted gene knockout to generate HCT116 Bax À/À cells (Zhang et al., 2000) .
Here, we show that Bax-negative HCT116 Bax À/À or the DU145 mock transfectants are fully resistant to TRAIL-induced apoptosis at TRAIL concentrations up to 100 ng/ml (Figures 1a, b and 2a, b and von Haefen et al., 2004) . In contrast, 18% (HCT116 wild type, Figure 1b ) to 19% (DU145-Bax, Figure 2b ) of the Baxpositive cells treated with a low TRAIL concentration of 20 ng/ml TRAIL showed genomic DNA fragmentation after an incubation period of 72 h. Higher TRAIL doses of 80-100 ng/ml induced apoptosis in 35% of Bax wild-type HCT116 cells (von Haefen et al., 2004) or Bax-reconstituted DU145 (Figure 2b ). Thus, dose response curves for TRAIL-induced apoptosis in these carcinoma cells follow a similar kinetic but show a lower degree of sensitivity in carcinoma (von Haefen et al., 2004) , as compared with lymphoid cells (Rudner et al., 2005) .
Likewise, induction of apoptosis by IR was entirely dependent on Bax in HCT116 cells. There, an IR dose of 20 Gy induced apoptosis in 49% of the Bax-positive HCT116 wild-type cells, whereas HCT116 Bax À/À cells were completely resistant against IR-induced apoptosis (Figure 1c) . In contrast and to our surprise, both Baxnegative DU145 mock transfectants and Bax-re-expressing DU145-Bax cells underwent IR-induced apoptosis to an almost identical extent with 47-55% apoptosis at 20 Gy IR (Figure 2c ). Thus, loss of Bax may result in resistance to IR (in HCT116) but loss of p53 and Bax obviously did not affect apoptosis induction in DU145 cells. This might be due to the loss of p53 function and the resulting failure to express p21 CIP/WAFÀ1 in DU145. Both events were reported earlier to facilitate IRinduced apoptosis (Waldman et al., 1996; Bunz et al., 1999) . Apparently, this mode of cell death involves Bax-independent mechanisms. Figure 3c ) in the absence of TRAIL. Sensitization for IR-induced cell death by TRAIL was observed in HCT116 Bax wildtype cells at IR doses from 2.5 to 10 Gy with 38% apoptosis at 2.5 Gy and 67% apoptosis at 10 Gy at 72 h after IR (Figure 3c ). In contrast, there was no enhanced apoptosis induction at all in the HCT116 Bax À/À cells (Figure 3b and d) . A very similar, entirely Baxdependent sensitization by TRAIL for IR-induced apoptosis was observed in DU145 cells (Figure 4a and b). There, DU145-Bax cells underwent 7-21% IRinduced apoptosis at 1.2-10 Gy at 72 h after IR (Figure 4b ). Addition of TRAIL resulted in a dramatic increase of IR-induced apoptosis in 56-77% of the DU145-Bax cells at 72 h. In contrast, TRAIL had no effect at all on the Bax-negative DU145 mock cells (Figure 4a and b). Interestingly, this synergistic induction of apoptosis was not apparent early after IR. At 24 h after IR, we only observed TRAIL-induced apoptosis and no IR-induced apoptosis. Synergism was observed as soon as IR-induced apoptosis was detectable (48 h) and became readily detectable already at low IR doses of 1.2 Gy after 72 h. Incubation for 96 h did not add much to the synergistic induction of apoptosis by combined TRAIL þ IR.
Bax mediates activation of the mitochondrial apoptosis pathway. Oligomerization and membrane insertion of activated Bax triggers release of cytochrome c, Smac, and other proapoptotic factors from the mitochondria (reviewed in Daniel et al., 2003) . To determine whether (Figure 5b) . In analogy to the measurement of apoptotic DNA fragmentation, a higher rate of DC m breakdown was observed when both stimuli were combined. There, a low induction of DC m breakdown in 16% of the Bax-negative DU145 mock cells became apparent, whereas 36% of the DU145-Bax cells displayed activation of the mitochondrial death pathway. This effect was, however, at best additive. This is in agreement with data obtained when TRAIL-mediated sensitization for 5-FU-induced apoptosis was investigated (von Haefen et al., 2004) . This indicates that Bax might involve signaling compartments apart from the mitochondria when mediating the synergistic induction of cell death by TRAIL plus IR (or 5-FU). This assumption is supported by measurement of Bax activation, that is, the N-terminal conformational switch in Bax, upon exposure to TRAIL and/or IR ( Figure 6 ). There, both low-dose TRAIL at 10 ng/ml and IR at 10 Gy failed to induce strong Bax activation. In contrast, the combination of low-dose TRAIL plus IR synergistically triggered Bax activation in Bax-expressing DU145 cells.
Caspase activation by TRAIL plus IR
To further analyse the underlying mechanism of the Bax-mediated synergistic interaction in apoptosis induction, we determined the activation of the caspase cascade in relation to IR and death receptor signaling by TRAIL in the DU145 system. Figure 7 shows that low doses of TRAIL trigger processing of procaspase-8 to the p18 fragment of active caspase-8. This activation of caspase-8 could be detected at 24 and 48 h after addition of TRAIL regardless of the absence or presence of Bax. Activation of caspase-8 was paralleled by a decrease in the expression of the Bid proform and processing of procaspase-3 to the p19 cleavage product. Thus, processing of procaspase-8 and Bid cleavage follow the kinetics of TRAIL-induced apoptosis that can be detected as early as 24 h after addition of the death ligand. In contrast, processing of procaspase-9 to the p37 cleavage product was not detectable before at 24 h. Caspase-9 processing was, however, observed at 48 h, that is, when IR-induced apoptosis became detectable. This caspase-9 cleavage was observed only in DU145-Bax but not in the Bax-negative DU145 mock cells. In DU145-Bax cells, both TRAIL and the combined IR/TRAIL induced procaspase-9 processing to the p37 product that was accompanied by processing of procaspase-3 to the active p17 subunit. Caspase-9 processing was more pronounced in HCT116 cells (Figure 8 ). Low-dose TRAIL or IR alone triggered a marginally detectable cytochrome c release, whereas the combination of both stimuli induced strong release of cytochrome c in Bax-proficient but not in Bax-deficient HCT116 cells. IR by itself induced expression of Bax but not Bak in the HCT116 wild-type cells. Bax-proficient cells showed a slight increase in caspase-9 processing upon IR alone, whereas cells treated with TRAIL or TRAIL plus IR displayed almost complete disappearance of the zymogen. This was paralleled by increased caspase-3 processing to the p16/17 product and almost complete disappearance of the Bid proform. Thus, caspase-9 and Bid processing might occur in consequence of TRAIL-induced caspase-3 activation, as observed earlier in other systems such as Smac-induced apoptosis . Again, TRAIL-induced Bid and caspase-9 processing was entirely Bax dependent and did not occur in the Bax-deficient HCT116 cells.
Notably, both Bax-deficient HCT116 Bax À/À and DU145 cells express significant levels of Bak (Figure 8 and Gillissen et al., 2003; Prokop et al., 2003; von Haefen et al., 2004) . Thus, Bak expression per se is not sufficient to facilitate crosssensitization between TRAIL and IR.
Discussion
In the present study, we addressed the role of the proapoptotic multidomain Bcl-2 homolog Bax in Previous studies highlighted the use of TRAIL or other death ligands in cancer therapy as a single agent. The majority of these studies showed that TRAIL or other death ligands induce apoptosis in cancer cells in a more or less selective fashion. The induction of cell death upon death receptor ligation is, however, incomplete and tends to select for death receptor signaling and rapid outgrowth of resistant tumors (Dhein et al., 1992; Coney et al., 1994; LuckingFamira et al., 1994; Daniel et al., 2001) . To circumvent this apparent capacity of death ligands to select for resistant phenotypes, the concept of employing TRAIL not only as a single agent (Ashkenazi et al., 1999; Walczak et al., 1999) but also in combination with other, DNA-damaging anticancer therapies was developed (Bonavida et al., 1999; Gliniak and Le, 1999; Wen et al., 2000; Belka et al., 2001) . These reports demonstrated that TRAIL sensitizes cancer cells for drug-or irradiation-induced cell death. In fact, the combined treatment of cancer cells with TRAIL together with conventional, DNA-damaging drugs or IR overcame resistance and resulted in the improved elimination of cancer cells in vitro and in vivo. Apart from circumventing resistance, our present data and results from other groups show that the combination of anticancer drugs with TRAIL allows to employ significantly lower, subtoxic doses of drugs or IR to achieve tumor cell killing.
In view of our previous findings on clinical resistance to anticancer therapy in consequence of disrupted p53/ Bax signaling (Sturm et al., 1999 Prokop et al., 2000; Bosanquet et al., 2002; Gu¨ner et al., 2002; Mrozek et al., 2002) , we aimed to clarify the role of Bax in TRAIL-induced sensitization for drug-induced cell death in human carcinoma. Here, we show that TRAIL critically depends on Bax to exert its sensitizing effect. Thus, Bax was crucial to mediate the synergistic effect of TRAIL and IR to activate the mitochondrial pathway of apoptosis and the caspase cascade. To this end, we Bax mediates synergy between TRAIL and irradiation J Wendt et al employed two Bax-deficient cell systems, Bax-frameshift-mutated DU145 cells where Bax was stably reexpressed and HCT116 cells where the Bax gene was disrupted by targeted gene knockout (Zhang et al., 2000) . In addition, DU145 cells carry a mutated p53 that fails to activate p53 target gene expression including the CDK inhibitor p21 CIP/WAFÀ1 . Disruption of Bax in these cells results in a pronounced resistance to the anthracycline epirubicin , ceramide , and the BH3-only protein Nbk , whereas the response to other stimuli triggering the mitochondrial pathway of apoptosis such as p14 ARF or Smac was not affected in consequence of the loss of Bax.
Here, we show that Bax is a critical player when analysing the capacity of TRAIL and IR to induce apoptosis in this system: loss of Bax abrogated sensitivity to TRAIL-induced apoptosis in both DU145 and HCT116 cells. Thus, both carcinoma cells are type II cells that critically depend on the mitochondrial pathway to execute the cell death program upon death receptor ligation. In the same vein, we demonstrated in malignant melanoma that the sensitivity to CD95/Fas-induced apoptosis is impaired upon deregulated overexpression of Bcl-2 (Raisova et al., 2000 (Raisova et al., , 2001 . Similarly, Bcl-2 overexpression was shown to result in resistance to TRAIL-induced apoptosis in type II cells (Fulda et al., 2002) . In contrast, another report showed that TRAIL may overcome resistance in type I cells (Walczak et al., 2000) . More light was shed onto this apparent discrepancy by a recent report where the effect of low or high doses of TRAIL was studied in Bcl-2-or Bcl-x L -overexpressing Jurkat cells (Ballestrero et al., 2004) . There, Bcl-x L significantly inhibited induction of apoptosis by TRAIL at doses from 1 to 10 ng/ml, whereas higher doses of 50-100 ng/ml overcame Bcl-x L -mediated resistance to apoptosis. Similarly, 50 ng/ml TRAIL sensitized Bcl-2-or Bcl-x L -overexpressing Jurkat cells for apoptosis induced by the anticancer drugs doxorubicin, etoposide, and oxaliplatin. This indicates that anticancer drugs in combination with TRAIL trigger a type I-like (i.e. Bcl-2 insensitive) death program at high doses, whereas these drugs plus lowdose TRAIL induce cell death in a type II-like manner (i.e. Bcl-2 and Bcl-x L dependent). This is very much in accordance with our recent work where we show for TRAIL itself that low doses mediate a type II response, whereas high TRAIL doses trigger Bcl-2-independent Figure 7 Western blot analysis of caspase and Bid processing in DU145 cells. Cytosolic extracts were prepared and subjected to Western blot analysis for processing of procaspase-3, -8, and -9 or Bid after 24 or 48 h incubation with TRAIL (10 ng/ml) or 5-10 Gy IR alone or in combination. Positions of molecular mass markers are indicated at the right. The experiment was repeated and similar results were obtained. b-Actin served as a control for equal protein loading Figure 8 Western blot analysis of cytochrome c release, caspase and Bid processing in HCT116 cells. Cytosolic extracts were prepared from Bax wild-type or Bax À/À HCT116 cells and subjected to Western blot analysis for expression of Bax, Bak, release of cytochrome c, and processing of procaspase-3, -8, and -9 or Bid after 48 h incubation with TRAIL (10 ng/ml) or 5-10 Gy IR alone or in combination. Positions of molecular mass markers are indicated at the right. The experiment was repeated and similar results were obtained. b-Actin served as a control for equal protein loading Bax mediates synergy between TRAIL and irradiation J Wendt et al cell death, that is, type I-like apoptosis (Rudner et al., 2005) . Altogether, either loss of Bax or overexpression of Bcl-2 may cause resistance to death receptor-induced apoptosis. Notably, loss of Bax abrogated sensitivity for IR-induced cell death in p53 wild-type HCT116 cells, whereas sensitivity for IR was apparently not affected by Bax-loss in p53-mutated DU145 cells. Thus, loss of Bax may result in resistance to IR-induced apoptosis but the DU145 system shows that IR may also induce Baxindependent cell death. In fact, the loss of function p53 mutation in DU145 might be the underlying pathomechanism for the discrepant behavior of HCT116 and DU145 regarding Bax and resistance to IR. Evidence for this comes from data obtained in the HCT116 system. There, disruption of p53 or p21 CIP/WAFÀ1 abrogates cell cycle checkpoint control upon IR and results in a drastically enhanced sensitivity to IR-induced apoptosis (Waldman et al., 1996; Bunz et al., 1999) . To further address this mechanism and to delineate the roles of Bax and p21
CIP/WAFÀ1 in IR-induced cell death, we generated HCT116 cells that are not only deficient for Bax or p21 CIP/WAFÀ1 but are both Bax and p21 CIP/WAFÀ1 deficient (unpublished). The analysis of IR-induced apoptosis in these HCT116 genotypes shows that loss of Bax only partially inhibits the sensitization that is achieved upon disruption of p21 CIP/WAFÀ1 . This, in turn, suggests that sensitization for DNA damage-induced cell death achieved by disruption of p53/p21 CIP/WAFÀ1 checkpoint control is at least in part independent from Bax. This is well in accordance with the data obtained in the p53 mutant DU145 regarding IR-induced apoptosis. There, IR induced a Bax-independent mode of apoptosis.
Nevertheless, the sensitization for IR-induced cell death by TRAIL (or vice versa) is entirely dependent on Bax. This is surprising as both DU145 and HCT116 express significant levels of Bak von Haefen et al., 2004) . Thus, Bak is not sufficient to mediate the sensitization for IR-induced cell death by TRAIL. Notably, overexpression of Bak failed to mediate sensitization and synergism of TRAIL for drug-induced apoptosis. This indicates that the limited relevance of Bak in this system does not occur due to a Bak defect (von Haefen et al., 2004) . Such a model of Bax-specific and Bak-independent apoptosis is well in agreement with recent data that establish that Bax and Bak work in overlapping but distinct signaling cascades. Such a Bax-specific effect in apoptosis control was reported beforehand for the BH3-only proteins Nbk and Puma Yu et al., 2003) and crosssensitization by TRAIL and 5-FU (von Haefen et al., 2004) .
The latter aspect of IR-induced cell death is of quite some interest as loss of Bax is a common event in a variety of cancers treated in the clinics by the use of IR including breast , esophageal Gu¨ner et al., 2002) , and colorectal carcinoma (Sturm et al., 1999; Schelwies et al., 2002) . Regarding alternative pathways of IR-induced cell death, drug-induced death receptor signaling has been implicated but does not seem to be a valid explanation in the present setting. First, there is evidence that IR does not rely on death receptors to execute the apoptotic program . Second, the majority of cancer cells including DU145 are type II cells and mediate death receptor signaling at least partially through the mitochondrial pathway (von Haefen et al., 2004) . Activation of the mitochondrial pathway upon exposure to TRAIL or IR is, however, disrupted in cells lacking Bax as evidenced by the current data. If this is the case, the problem arises why the Bax-homologous proapoptotic Bak is not sufficient to complement Bax deficiency. An attractive possibility to explain such a different behavior of Bax and Bak as compared with murine fibroblasts ) might reside in the expression of a Bak inhibitor in human carcinoma. In fact, the VDAC2 protein was recently described to interfere with Bak function (Cheng et al., 2003) and therefore might represent such a Bak antagonist.
Nevertheless, overexpression of wild-type Bak sensitizes drug-resistant cells for mitochondrial activation and apoptosis (Radetzki et al., 2002; von Haefen et al., 2004) . In fact, it was suggested that Bax and Bak play a redundant role and that only inactivation of both is capable to fully disrupt apoptosis signaling by death receptors via tBid ). In the same context, a variety of data showed that the death receptor-induced apoptosis is linked to the mitochondrial machinery through the BH3-only protein Bid (Eskes et al., 2000; Korsmeyer et al., 2000) . Bid is cleaved by a caspase-8 to truncated Bid (tBid) (Luo et al., 1998) . The processed tBid in turn was shown to activate mitochondria in a Bax-dependent manner (Eskes et al., 2000) . This is in agreement with our present data showing that TRAIL triggers caspase-8 processing, Bid cleavage and sensitizes tumor cells by a Bax-dependent mechanism for caspase-9 and -3 processing followed by execution of apoptosis. Given this significant dependence on Bax, our present data indirectly suggested that Bak cannot fully complement Bax and that Bid might preferentially interact with Bax but not Bak. Even while tBid was shown to induce oligomerization of both Bax and Bak (Korsmeyer et al., 2000) , our data depict that the functions of Bax and Bak are not fully redundant. This is, however, in opposition to a recent report that showed Bax-dependence in TRAIL-induced chemosensitization in HCT116 cells (LeBlanc et al., 2002) . This report showed, by the use of HCT116 colon carcinoma cells, that inactivation of Bax results in resistance to TRAIL-induced apoptosis and that this resistant phenotype can be rescued by combining TRAIL with anticancer drugs, presumably through induction of Bak protein expression. Nevertheless, we observed here that Bak does not replace Bax in sensitization for apoptosis by either TRAIL alone or TRAIL plus IR. A recent study performed in human glioblastoma cells sheds more light into this apparent discrepancy in relation to our present data. There, a nonredundant function of Bax and Bak in Bid-mediated apoptosis was described (Cartron et al., 2003) . In fact, caspase-8 generated 15 kDa Bid fragments that acted in a Bak-dependent manner, whereas granzyme B-generated 13 kDa Bid fragments were prone to interact with Bax. Such a differential interaction of Bid cleavage products with Bax or Bak may well explain our present observation of a Bax-specific sensitization for TRAIL/ IR-induced apoptosis. There remains, however, a possibility that another BH3-only protein different from Bid mediates the synergism between TRAIL and IR or other anticancer treatment modalities.
In a previous study, a minimalistic signaling model for TRAIL/IR crosssensitization was defined. There, a requirement for TRAIL receptors DR4 or DR5, caspase-8, and FADD was established. The present data add Bax to this model and underline the notion that Bax but not Bak mediates crosssensitization between TRAIL and IR (Marini et al., 2003) . A model for the signaling events responsible for crosssensitization by TRAIL and IR is shown in Figure 9 . Altogether, our present data indicate a higher degree of complexity regarding the role of the multidomain Bcl-2 homologs Bax and Bak. Apparently, these two multidomain Bcl-2 homologs share overlapping functions in some apoptosis signaling conditions but distinct regulatory activities in other pathways initiated upon IR and TRAIL receptor ligation in human carcinoma cells.
Materials and methods
Cell culture
Control retroviral vector (HyTK-mock-transfected) and HyTK-Bax-transfected DU145 prostate carcinoma cells were grown in DMEM medium and HCT116 Bax wild-type and Bax k.o. cells (Zhang et al., 2000) were cultured in McCoy's 5A medium both supplemented with 10% fetal calf serum (FCS), 100 000 U/l penicillin, and 0.1 g/l streptomycin. Media and culture reagents were from Invitrogen (Karlsruhe, Gemany). Confluent cells were subcultured every 3-4 days after detaching the cells with 0.1% trypsin, 0.02% ethylenediamine tetraacetic acid (EDTA) in phosphatebuffered saline (PBS). A Cs-137 g-source was used for ionizing radiation experiments.
Antibodies and reagents
Monoclonal anti-human Bax antibody (clone YTH-2D2) was from Trevigen (Gaithersburg, MD, USA) and used at 1 : 10 000. Polyclonal rabbit anti-Bak antibody was from DakoCytomation, Hamburg, Germany and used at 1 : 100. Polyclonal anti-human actin antibody produced in rabbits was from Sigma-Aldrich, Taufkirchen, Germany and was used at 1 : 100. Polyclonal anti-human caspase-9 produced in goat was from R&D Systems GmbH (Wiesbaden-Nordenstadt, Germany) and was used at 1 : 1000. Polyclonal anti-human caspase-3 produced in goat was from R&D Systems GmbH (Wiesbaden-Nordenstadt, Germany) and was used at 1 : 1000. Hybridoma supernatants of the monoclonal murine anticaspase-8 antibody were kindly provided by Dr K SchulzeOsthoff and used at 1 : 3. The rabbit anti-Bid antiserum was from R&D Systems GmbH (Wiesbaden-Nordenstadt, Germany) and employed at 1 : 1000. Secondary anti-rabbit, anti-goat, and anti-mouse horseradish peroxidase (HRP)-conjugated antibodies were from Promega (Mannheim, Germany) or Southern Biotechnology Associates (Birmingham, AL, USA) and were used at 1 : 5000. RNase A was from Roth (Karlsruhe, Germany).
Measurement of DNA fragmentation
DNA fragmentation was measured essentially as described . After treatment for 72 h with different concentrations of TRAIL and/or doses of IR, cells were detached by trypsination and collected by centrifugation at 300 g for 5 min. Cells were first washed with complete cell Figure 9 Signaling model of TRAIL-mediated sensitization for apoptosis induced by IR. IR induces DNA damage and triggers the mitochondrial apoptosis signaling cascade. Activation of mitochondria occurs through Bax-dependent and -independent mechanisms, the latter, for example, via the Bax homolog Bak. In contrast, death receptors like the TRAIL receptors 1 (DR4) and 2 (DR5) recruit a signal transduction complex, the death-inducing signaling complex (DISC) to the membrane. This complex consists of the oligomerized death ligand, that is, TRAIL, the TRAIL receptor, the adapter molecule FADD recruited to the death domain (DD) of the cytoplasmic part of the TRAIL death receptor, and the initiator caspase-8 (or -10). ) is recruited to the DISC via FADD by interaction of the death effector domains (DED) in both molecules. Caspase-8 is activated in the DISC by autocatalysis and processes the effector procaspaseculture medium to stop tryptic digestion and then with PBS at 41C. Cells were fixed in PBS/0.74% (v/v) formaldehyde on ice for 30 min, pelleted, incubated with ethanol/PBS (2 : 1, v/v) for 15 min, pelleted and resuspended in PBS containing 40 mg/ml RNase A (Roth (Karlsruhe, Germany)). RNA was digested for 30 min at 371C. Cells were pelleted again and finally resuspended in PBS containing 50 mg/ml propidium iodide (Sigma-Aldrich, Taufkirchen, Germany). Nuclear DNA fragmentation was quantified by flow cytometric determination of hypodiploid DNA. Data were collected and analysed using a FACScan (Becton Dickinson; Heidelberg, Germany) equipped with the CELLQuest software. Data are given in % hypoploidy (subG1), which reflects the number of apoptotic cells.
Measurement of mitochondrial permeability transition
After incubation for 24-48 h with different concentrations of TRAIL and/or doses of IR, cells were detached by trypsination and collected by centrifugation at 300 g, 41C for 5 min. Mitochondrial permeability transition was then determined by staining the cells with 5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethyl-benzimidazolylcarbocyanin iodide (JC-1; Molecular Probes, Leiden, The Netherlands) as described . 1 Â 10 5 cells were resuspended in 500 ml phenol red-free RPMI 1640 without supplements and JC-1 was added to give a final concentration of 2.5 mg/ ml. Cells were incubated for 30 min at 371C and moderate shaking. Control cells were likewise incubated in the absence of JC-1 dye. Cells were harvested by centrifugation at 300 g, 41C for 5 min, washed with ice-cold PBS and resuspended in 200 ml PBS at 41C. Mitochondrial permeability transition was then quantified by flow cytometric determination of cells with decreased fluorescence as measured in the FL2 channel (550 to 650 nm), that is, with mitochondria displaying a lower membrane potential. Data were collected and analysed using a FACScan (Becton Dickinson; Heidelberg, Germany) equipped with the CELLQuest software. Data are given in % cells with low DCm, which reflects the number of cells undergoing mitochondrial apoptosis.
Measurement of conformational change of Bax by flow cytometry
Measurement of conformational change of Bax was performed essentially as described . After induction of apoptosis for 24 h, cells were detached by trypsination and collected by centrifugation at 300 g, 41C for 5 min. Cells were washed with PBS at 41C, fixed in 1 ml PBS/0.5% paraformaldehyde (v/v) on ice for 30 min and washed in PBS/1% FCS. Staining with conformation specific anti-Bax NT antibody (Upstate Biotechnology) was performed by incubating cells in 50 ml staining buffer (PBS, 1% FCS, 0.1% saponin) containing 0.1 mg of the respective antibody on ice for 30 min. Then, cells were washed in staining buffer, resuspended in 50 ml staining buffer containing 0.1 mg fluorescein-labeled F(ab 0 )2 goat antirabbit IgG (H þ L) antiserum (Jackson Immuno Research; West Grove, PA, USA) and incubated on ice for 30 min in the dark. After washing in PBS/1% FCS, intracellular staining of Bax was immediately measured with logarithmic amplification in the FL-1 channel of a FACScan (Becton Dickinson). Data are given in % cells with increased fluorescence, which reflects the number of cells containing Bax with a conformational change in the N-terminal region.
Immunoblotting
Cells were washed twice with PBS and lysed in buffer containing 10 mM Tris/HCl, pH 7.5, 300 mM NaCl, 1% Triton X-100, 2 mM MgCl 2 , 5mM EDTA, 1 mM pepstatin, 1 mM leupeptin, and 0.1 mM phenylmethylsulfonyl fluoride (PMSF). Protein concentration was determined using the bicinchoninic acid assay from Pierce (Rockford, IL, USA), and equal amounts of protein (usually 30 mg per lane) were separated by SDS-PAGE as described . Then, blotting of proteins onto nitrocellulose membranes (Schleicher and Schuell, Dassel, Germany) was performed exactly as described . After blotting, the membrane was blocked for 1 h in PBST (PBS, 0.05% Tween-20) containing 3% nonfat dry milk and incubated with primary antibody for 1 h. After the membrane had been washed three times in PBST, secondary antibody in PBST was applied for 1 h. Finally, the membrane was washed in PBST again and the ECL-enhanced chemiluminescence system from Amersham Buchler (Braunschweig, Germany) was used to visualize the protein bands in question.
